16th May 2022 | Pharma Updates
SII seeks approval from the governmentto develop and stockpile qHPV vaccine
Serum Institute of India has requested permission from the government to manufacture and stockpile an indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer.
Stelis Biopharma asks PM Modi for vaccines after failing to sell Sputnik Light stock
Bengaluru-based Stelis Biopharma has written to Prime Minister Narendra Modi, requesting that the vaccines be procured for inoculating citizens in India or supplying to other countries under the Vaccine Maitri programme.
Pfizer pushed back the distribution of COVID vaccines
Pfizer and its German partner BioNTech SE recently announced that delivery of their COVID-19 vaccines to the European Union (EU) may be delayed by three months as the bloc prepares for a possible fall booster campaign.
'One Step' platform to provide accurate information to persons travelling to India for treatment: Mandaviya
Union Health Minister Mansukh Mandaviya proposed the establishment of facilitation centres at Indian embassies throughout the world for persons who want to go to India for medical treatment.
Treatment from Boehringer Ingelheim halted the decrease of lung function in adults with idiopathic pulmonary fibrosis
Boehringer Ingelheim reported promising 12-week Phase II data for BI 1015550 which demonstrated a reduction in the rate of lung function decline in patients with IPF.
Eli Lilly's diabetic portfolio expands with FDA approval of potential blockbuster drug
USFDA has approved a new type of medication for type 2 diabetes, Mounjaro (tirzepatide), a once-weekly injection, was found to be more effective than other current medications at managing blood sugar levels.
Sandoz launched the first US generic version ofthe blockbuster Esbriet
Novartis’ Sandoz has launched the first completely substitutable generic version of Roche’s blockbuster idiopathic pulmonary fibrosis (IPF) medication Esbriet in the United States.
